Simpler Grants.gov #PAR-25-325

NCI Solicits Research on Biospecimen Science for Clinical Assay Development

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is seeking research proposals to address challenges in clinical assay development caused by preanalytical variability in biospecimens. - Government Buyer: - National Institutes of Health (NIH), National Cancer Institute (NCI) - Scope of Research: - Focus on biospecimen science to improve clinical assay development and analytical validation - Investigate preanalytical variability in collection, processing, and storage of biospecimens - Biospecimens include tumor tissue biopsies, blood (liquid biopsies), tissue swabs, secretions, aspirates, feces, sweat, urine, cerebrospinal fluid, breast milk, and saliva - Research should address how preanalytical conditions impact biomarker quantification across testing platforms - Goal is to standardize biopsy handling practices based on scientific evidence - Products/Services Requested: - No specific products or OEMs requested; this is a research grant opportunity - Service: Research on biospecimen science approaches for clinical assay development - Eligibility and Requirements: - Open to businesses, educational institutions, governments, nonprofits, tribal governments, and non-U.S. entities - Clinical trials are not allowed under this opportunity - Funding instrument is a cooperative agreement - Notable Requirements: - Emphasis on extramural research - Applicants must design experiments to address preanalytical variability - Standardization of biospecimen handling is a key objective - No OEMs or commercial vendors are specified, as this is a research-focused grant opportunity

Description

The National Cancer Institute (NCI) seeks extramural research to address challenges in clinical assay development and analytical validation caused by preanalytical variability in various biospecimens including tumor tissue biopsies and liquid biopsies. Research may focus on small biopsies, blood, tissue swabs, bodily fluids, and other biospecimens to understand how preanalytical conditions affect biomarker quantification across testing platforms. The goal is to improve biomarker clinical assay development by standardizing biopsy handling practices based on evidence. This funding opportunity supports cooperative agreements and is open to a wide range of applicants including businesses, educational institutions, governments, nonprofits, and other organizations.

View original listing